<DOC>
	<DOCNO>NCT02381496</DOCNO>
	<brief_summary>This three-part study ass tolerability , safety , pharmacodynamics , pharmacokinetics ascend single dos ( include food interaction ) ACT-453859 healthy male subject , ascend multiple dos ACT-453859 healthy male female subject , multiple dos setipiprant ( ACT-129968 ) healthy male female subject .</brief_summary>
	<brief_title>A Study Assess Tolerability , Safety , Pharmacodynamics , Pharmacokinetics Ascending Single Doses ( Including Food Interaction ) Ascending Multiple Doses ACT-453859 , Multiple Doses Setipiprant ( ACT-129968 )</brief_title>
	<detailed_description>Part A study single-center , randomize , double-blind , placebo-controlled , single-ascending dose ( SAD ) design healthy male subject . In cohort , eight subject randomize follow : - Six male subject receive single oral dose ACT-453859 , fast condition . - Two male subject receive match placebo , fasted condition . The dos ACT-453859 1 , 3 , 10 , 30 , 100 , 300 , 800 mg . Subjects one cohort ( 100 mg dose cohort ) come back second period treatment fed condition . Part B single-center , randomize , double-blind , placebo-controlled multiple-ascending dose ( MAD ) design healthy male female subject . In 3 cohort , eight subject randomize receive multiple dos ACT-453859 placebo day 7 day follow : - Three male subject receive ACT-453859 . - Three female subject receive ACT-453859 . - One male subject receive matching placebo . - One female subject receive matching placebo . The dos ACT-453859 10 , 100 , 800 mg per day . Part C single-center open-label design consist multiple oral dos setipiprant give sequential design healthy male female subject . Eight subject randomize receive multiple dos setipiprant 7 day ( single dose Day 7 ) , Treatment Period I ( TPI ) Treatment Period II ( TPII ) , follow : - Four male subject receive setipiprant 500 mg twice day ( b.i.d . ) TPI 1000 mg b.i.d . TPII . - Four female subject receive setipiprant 500 mg b.i.d . TPI 1000 mg b.i.d . TPII .</detailed_description>
	<criteria>Signed informed consent . Healthy male subject ( Part A ) , healthy male female subject Parts B &amp; C. Hematology , coagulation ( Part A Part B ) , clinical chemistry , urinalysis test result deviate normal range clinically relevant extent . No clinically significant finding physical examination . Body mass index 18.0 28.0 kg/m^2 . Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , heart rate 4590 beat per minute . 12lead electrocardiogram without clinically relevant abnormality . Negative result urine drug screen alcohol breath test . Able willing refrain sunbathing , prolong sun exposure , artificial sunlight exposure solarium , limit skin eye exposure sunlight use appropriate precaution first dose safety followup visit Parts A B . Ability communicate well investigator local language , understand comply requirement study . For male subject : consent female partner use medically acceptable method contraception throughout entire study period 90 day study complete . For male subject : agree donate sperm first drug administration 90 day completion study . For Part C , woman childbearing potential must negative serum pregnancy test negative urine pregnancy test predose Day 1 ( treatment period Part C ) . Women childbearing potential must consistently correctly use reliable method contraception , sexually inactive vasectomized partner . Willing adhere prohibition restriction specify protocol . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Veins unsuitable intravenous puncture either arm . Treatment prescribed overthecounter medication within 2 week prior first study drug administration . Treatment substance know inhibit cytochrome P ( CYP ) enzyme drug metabolism . Treatment substance know induce CYP enzyme drug metabolism . Treatment another investigational drug within 3 month prior participate four investigational drug study within 1 year prior Screening . Subjects participate one part study . History clinical evidence alcoholism drug abuse within 3year period prior Screening . History clinical evidence disease , and/or existence surgical medical condition , might interfere absorption , distribution , metabolism excretion study drug . Excessive caffeine consumption . Smoking , tobacco use , use nicotine product within 3 month inability refrain smoke course study . Loss 250 mL blood , equivalent amount plasma , within 3 month prior Screening . Positive result hepatitis serology , except vaccinated subject subject past resolve hepatitis . Positive result human immunodeficiency virus serology . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol . Legal incapacity limit legal capacity . Pregnant lactating woman . Known allergic reaction hypersensitivity excipients drug formulation . Difficulty fast consume standardized meal . Difficulty swallow whole tablet capsule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ACT-453859</keyword>
	<keyword>ACT-463036</keyword>
	<keyword>Setipiprant</keyword>
	<keyword>Tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>